SG11201804597TA - Vaccination with mica/b alpha 3 domain for the treatment of cancer - Google Patents
Vaccination with mica/b alpha 3 domain for the treatment of cancerInfo
- Publication number
- SG11201804597TA SG11201804597TA SG11201804597TA SG11201804597TA SG11201804597TA SG 11201804597T A SG11201804597T A SG 11201804597TA SG 11201804597T A SG11201804597T A SG 11201804597TA SG 11201804597T A SG11201804597T A SG 11201804597TA SG 11201804597T A SG11201804597T A SG 11201804597TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- cancer
- rule
- alpha
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000010445 mica Substances 0.000 title abstract 2
- 229910052618 mica group Inorganic materials 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263377P | 2015-12-04 | 2015-12-04 | |
| US201662422454P | 2016-11-15 | 2016-11-15 | |
| PCT/US2016/064969 WO2017096374A1 (en) | 2015-12-04 | 2016-12-05 | Vaccination with mica/b alpha 3 domain for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804597TA true SG11201804597TA (en) | 2018-06-28 |
Family
ID=57590885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804597TA SG11201804597TA (en) | 2015-12-04 | 2016-12-05 | Vaccination with mica/b alpha 3 domain for the treatment of cancer |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10993971B2 (enExample) |
| EP (1) | EP3383426A1 (enExample) |
| JP (3) | JP7099956B2 (enExample) |
| KR (1) | KR20180088458A (enExample) |
| CN (1) | CN108770343A (enExample) |
| AU (3) | AU2016362597C1 (enExample) |
| BR (1) | BR112018010705A8 (enExample) |
| CA (1) | CA3005910A1 (enExample) |
| CL (3) | CL2018001470A1 (enExample) |
| CO (1) | CO2018006642A2 (enExample) |
| CR (2) | CR20180350A (enExample) |
| CU (2) | CU20210061A7 (enExample) |
| EA (1) | EA201891287A1 (enExample) |
| IL (1) | IL259490A (enExample) |
| MX (2) | MX2018006785A (enExample) |
| MY (1) | MY199248A (enExample) |
| NZ (1) | NZ742663A (enExample) |
| PE (2) | PE20181158A1 (enExample) |
| PH (1) | PH12018501170A1 (enExample) |
| RU (2) | RU2021109510A (enExample) |
| SG (1) | SG11201804597TA (enExample) |
| TN (1) | TN2018000187A1 (enExample) |
| WO (1) | WO2017096374A1 (enExample) |
| ZA (1) | ZA202204223B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021519599A (ja) | 2018-04-03 | 2021-08-12 | サノフイＳａｎｏｆｉ | 抗原性ｏｓｐａポリペプチド |
| EP3773708A2 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Antigenic epstein barr virus polypeptides |
| CN112512567A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性呼吸道合胞病毒多肽 |
| JP2021519596A (ja) | 2018-04-03 | 2021-08-12 | サノフイＳａｎｏｆｉ | フェリチンタンパク質 |
| TW202216776A (zh) | 2020-07-07 | 2022-05-01 | 美商康愈有限責任公司 | Mic抗體及結合劑以及其使用方法 |
| CN116396398B (zh) * | 2023-01-16 | 2024-07-16 | 四川大学 | 一种实现铁蛋白纳米颗粒可控自组装的方法以及基于该方法搭建的纳米颗粒抗原展示平台 |
| WO2024222886A1 (zh) * | 2023-04-28 | 2024-10-31 | 北京先声祥瑞生物制品股份有限公司 | 一种针对MICA/B靶点的mRNA肿瘤疫苗 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
| US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| EP0378881B1 (en) | 1989-01-17 | 1993-06-09 | ENIRICERCHE S.p.A. | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| EP0482068A1 (en) | 1989-07-14 | 1992-04-29 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| EP0471177B1 (en) | 1990-08-13 | 1995-10-04 | American Cyanamid Company | Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| WO1993021769A1 (en) | 1992-05-06 | 1993-11-11 | President And Fellows Of Harvard College | Diphtheria toxin receptor-binding region |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
| WO1998018931A2 (en) | 1996-10-31 | 1998-05-07 | Human Genome Sciences, Inc. | Streptococcus pneumoniae polynucleotides and sequences |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| EP1162999B1 (en) | 1999-03-19 | 2006-11-29 | Glaxosmithkline Biologicals S.A. | Vaccine against Streptococcus pneumoniae |
| JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
| CA2776522C (en) | 2001-10-01 | 2015-02-17 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
| US6706305B2 (en) | 2001-10-31 | 2004-03-16 | Conagra Foods Inc. | Low glycemic index bread |
| CN1659187A (zh) * | 2002-05-10 | 2005-08-24 | 新世纪药品有限公司 | 融合铁蛋白在疫苗和其他方面的应用 |
| WO2006050270A2 (en) | 2004-11-02 | 2006-05-11 | The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services | Compositions and methods for treating hyperproliferative disorders |
| GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| US8110196B2 (en) | 2005-04-29 | 2012-02-07 | Polytopas LLC | Methods and compositions for polytopic vaccination |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| WO2008036981A1 (en) | 2006-09-22 | 2008-03-27 | Dana-Farber Cancer Research, Inc. | Methods for treating mica-related disorders |
| US8182809B1 (en) * | 2008-09-08 | 2012-05-22 | University Of Washington | Methods for treating cancer by inhibiting MIC shedding |
| WO2011046842A1 (en) | 2009-10-12 | 2011-04-21 | The Regents Of The University Of California | Targeted nanoclusters and methods of their use |
| EP2514718A4 (en) | 2009-12-18 | 2013-09-04 | Kao Corp | METHOD FOR PRODUCING MESOPOROUS SILICONE ARTICLES |
| JP5603063B2 (ja) | 2009-12-21 | 2014-10-08 | 花王株式会社 | 複合シリカ粒子の製造方法 |
| RU2489169C2 (ru) * | 2010-10-12 | 2013-08-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) | Способ лечения онкологических заболеваний |
| US20140234316A1 (en) * | 2011-09-23 | 2014-08-21 | University Of Oslo | Vaccibodies targeted to cross-presenting dendritic cells |
| EP3210625B1 (en) | 2011-09-30 | 2019-08-28 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica) |
| BR112014019611A2 (pt) * | 2012-02-07 | 2017-06-27 | Innate Pharma | agentes de ligação mica |
| CN104244929B (zh) | 2012-04-16 | 2017-04-05 | 哈佛学院董事会 | 用于调节免疫反应的介孔二氧化硅组合物 |
| WO2014144791A2 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| CA2906356A1 (en) * | 2013-03-15 | 2014-09-18 | Novelogics Biotechnology, Inc. | Antibodies to mica and micb proteins |
| WO2015139020A2 (en) * | 2014-03-14 | 2015-09-17 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
-
2016
- 2016-12-05 TN TNP/2018/000187A patent/TN2018000187A1/en unknown
- 2016-12-05 CR CR20180350A patent/CR20180350A/es unknown
- 2016-12-05 US US15/781,448 patent/US10993971B2/en active Active
- 2016-12-05 KR KR1020187019140A patent/KR20180088458A/ko not_active Ceased
- 2016-12-05 CN CN201680080434.4A patent/CN108770343A/zh active Pending
- 2016-12-05 RU RU2021109510A patent/RU2021109510A/ru unknown
- 2016-12-05 JP JP2018528691A patent/JP7099956B2/ja active Active
- 2016-12-05 WO PCT/US2016/064969 patent/WO2017096374A1/en not_active Ceased
- 2016-12-05 NZ NZ742663A patent/NZ742663A/en unknown
- 2016-12-05 AU AU2016362597A patent/AU2016362597C1/en active Active
- 2016-12-05 CU CU2021000061A patent/CU20210061A7/es unknown
- 2016-12-05 PE PE2018001072A patent/PE20181158A1/es unknown
- 2016-12-05 EP EP16816550.4A patent/EP3383426A1/en active Pending
- 2016-12-05 CA CA3005910A patent/CA3005910A1/en active Pending
- 2016-12-05 MX MX2018006785A patent/MX2018006785A/es unknown
- 2016-12-05 SG SG11201804597TA patent/SG11201804597TA/en unknown
- 2016-12-05 CR CR20230116A patent/CR20230116A/es unknown
- 2016-12-05 MY MYPI2018000849A patent/MY199248A/en unknown
- 2016-12-05 BR BR112018010705A patent/BR112018010705A8/pt active Search and Examination
- 2016-12-05 CU CU2018000050A patent/CU24609B1/es unknown
- 2016-12-05 PE PE2022002801A patent/PE20230495A1/es unknown
- 2016-12-05 RU RU2018123307A patent/RU2747296C2/ru active
- 2016-12-05 EA EA201891287A patent/EA201891287A1/ru unknown
-
2018
- 2018-05-21 IL IL259490A patent/IL259490A/en unknown
- 2018-06-01 PH PH12018501170A patent/PH12018501170A1/en unknown
- 2018-06-01 CL CL2018001470A patent/CL2018001470A1/es unknown
- 2018-06-01 MX MX2022010194A patent/MX2022010194A/es unknown
- 2018-06-27 CO CONC2018/0006642A patent/CO2018006642A2/es unknown
-
2021
- 2021-02-19 US US17/180,183 patent/US20210299186A1/en not_active Abandoned
- 2021-05-13 CL CL2021001256A patent/CL2021001256A1/es unknown
-
2022
- 2022-03-21 AU AU2022201940A patent/AU2022201940B2/en active Active
- 2022-04-14 ZA ZA2022/04223A patent/ZA202204223B/en unknown
- 2022-06-30 JP JP2022105405A patent/JP7564842B2/ja active Active
-
2023
- 2023-10-26 CL CL2023003217A patent/CL2023003217A1/es unknown
-
2024
- 2024-02-19 US US18/581,148 patent/US20250064863A1/en active Pending
- 2024-09-27 JP JP2024167997A patent/JP2024177207A/ja active Pending
-
2025
- 2025-08-08 AU AU2025213685A patent/AU2025213685A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804597TA (en) | Vaccination with mica/b alpha 3 domain for the treatment of cancer | |
| SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201907402SA (en) | Population-based immunogenic peptide identification platform | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201805375PA (en) | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201807720TA (en) | Methods and systems for determining antibiotic susceptibility | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201805755SA (en) | Methods of administering hepcidin |